Scholar Rock Holding Corp SRRK
We take great care to ensure that the data presented and summarized in this overview for Scholar Rock Holding Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SRRK
View all-
Artal Group S.A. Luxembourg, N411.3MShares$106 Million10.78% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD8.21MShares$77.1 Million0.02% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA6.79MShares$63.7 Million38.03% of portfolio
-
Redmile Group, LLC San Francisco, CA6.42MShares$60.3 Million4.49% of portfolio
-
Black Rock Inc. New York, NY5.01MShares$47 Million0.0% of portfolio
-
State Street Corp Boston, MA4.17MShares$39.2 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.57MShares$33.6 Million1.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.97MShares$27.9 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X02.94MShares$27.6 Million0.33% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.17MShares$20.3 Million0.6% of portfolio
Latest Institutional Activity in SRRK
Top Purchases
Top Sells
About SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at SRRK
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 09
2024
|
Amir Nashat |
BUY
Other acquisition or disposition
|
Direct |
13,133
+12.71%
|
-
|
May 09
2024
|
Amir Nashat |
SELL
Other acquisition or disposition
|
Indirect |
598,533
-61.12%
|
-
|
May 09
2024
|
Amir Nashat |
BUY
Other acquisition or disposition
|
Indirect |
98,855
+39.33%
|
-
|
Apr 09
2024
|
Katie Peng |
BUY
Grant, award, or other acquisition
|
Direct |
26,825
+50.0%
|
-
|
Feb 16
2024
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
4,744
-2.2%
|
$71,160
$15.74 P/Share
|
Feb 16
2024
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,512
-1.68%
|
$37,680
$15.74 P/Share
|
Feb 16
2024
|
Caryn Parlavecchio CHRO |
SELL
Open market or private sale
|
Direct |
3,751
-2.32%
|
$56,265
$15.74 P/Share
|
Feb 16
2024
|
Jay T. Backstrom CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
11,614
-3.19%
|
$174,210
$15.74 P/Share
|
Feb 16
2024
|
Junlin Ho GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
3,489
-1.64%
|
$52,335
$15.74 P/Share
|
Feb 12
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
72,855
+50.0%
|
-
|
Feb 12
2024
|
Jay T. Backstrom CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
214,285
+37.04%
|
-
|
Feb 12
2024
|
Caryn Parlavecchio CHRO |
BUY
Grant, award, or other acquisition
|
Direct |
47,145
+22.6%
|
-
|
Feb 12
2024
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
70,715
+32.11%
|
-
|
Feb 12
2024
|
Tracey Sacco CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
49,285
+50.0%
|
-
|
Feb 12
2024
|
Junlin Ho GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
57,855
+21.42%
|
-
|
Feb 12
2024
|
Edward H Myles COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
53,570
+19.89%
|
-
|
Jan 16
2024
|
Caryn Parlavecchio CHRO |
SELL
Open market or private sale
|
Direct |
2,849
-2.43%
|
$42,735
$15.93 P/Share
|
Jan 16
2024
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,002
-2.48%
|
$30,030
$15.93 P/Share
|
Jan 16
2024
|
Junlin Ho GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
4,186
-2.64%
|
$62,790
$15.93 P/Share
|
Jan 16
2024
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
6,634
-3.93%
|
$99,510
$15.93 P/Share
|
Last 12 Months Summary
Other acquisition or disposition | 453K shares |
---|---|
Grant, award, or other acquisition | 593K shares |
Open market or private purchase | 6.58M shares |
Exercise of conversion of derivative security | 45.8K shares |
Other acquisition or disposition | 2.69M shares |
---|---|
Payment of exercise price or tax liability | 15.5K shares |
Open market or private sale | 142K shares |
Bona fide gift | 21.3K shares |